Kimberly-Clark Offers EU Remedies for $40 Billion Kenvue Acquisition

Key Facts

1Kimberly-Clark has submitted concessions to address EU antitrust concerns regarding its $40 billion bid for Kenvue.

In a move reflecting the strategic push to finalize a major consumer goods consolidation, Kimberly-Clark has formally submitted remedy proposals to the European Commission. These concessions are designed to address antitrust concerns raised by EU regulators regarding the company's $40 billion acquisition bid for Kenvue. According to reports, the submission aims to mitigate regulatory friction identified during the Commission's review process.

This regulatory progress occurs as market participants monitor the valuation of both entities, with Kimberly-Clark (KMB) closing at $98.91 and Kenvue (KVUE) closing at $17.86 as of September 22, 2026, per market data. Such proposals are a standard phase in large-scale M&A transactions, typically intended to increase the probability of securing mandatory regulatory clearance for the deal to proceed.

Traders are now watching for the Commission's response to these remedies, while KMB and KVUE shares maintain levels near their recent daily highs of $99.92 and $17.99 respectively (as of close September 22, 2026). Looking ahead, market sentiment in the region may be influenced by upcoming Eurozone inflation data, which remains a key indicator for the broader economic environment in which these regulators operate.